The Impact of Generics on Pharmaceutical Growth Opportunities - A growing threat that offers future opportunities

CBR Pharma Insights, LLC
October 1, 2011
SKU: CBRP3805466
Countries covered: United States

While generic penetration has been on the rise in the major developed markets for some time, the current and continuing difficult economic environment is stimulating political and payer actions to accelerate the trend.

Combined with this, pharma is experiencing a wave of blockbuster patent expiries, with almost $30 billion in US sales (at 2010 levels) exposed by the largest 10 drugs which are expected to experience generic competition for the first time in 2011-2012.

As a result, companies must focus on optimizing their late-stage lifecycle management strategies to maximize at-risk product revenues. But at the same, time generics should be considered not just as a threat but also as an opportunity going forward.

The report, “The Impact of Generics on Pharmaceutical Growth Opportunities”, has been written to support companies with their strategic plans to maximize revenues within the shifting pharmaceutical landscape. The insights, analysis, and support provided can be used by both the branded and generics side of the business.

Key Reasons to Purchase:
  • Compare your company’s lifecycle management strategies with those most appropriate for maximizing generic defense
  • Assess the opportunities available to move into the generics side of the pharmaceutical industry, both in the established and emerging markets
  • Understand the various opportunities that exist to optimize revenue in preparation for your product’s patent expiry
  • Benefit from the analysis of multiple case studies to help support your company’s/brand’s strategy moving forward
  • Learn from the assessments of actual tactics companies have taken, both branded & generic, to drive future revenue growth in this new era of generics



More Manufacturing, Packaging & Detailing reports by CBR Pharma Insights, LLC

Biosimilars - Biosimilars on the cusp of a new era by CBR Pharma Insights, LLC
Biosimilars - Biosimilars on the cusp of a new era The biosimilars market is undergoing rapid change with developments such as the recent approvals of ...
Pediatric Drug Development - Regulatory challenges and commercial opportunities by CBR Pharma Insights, LLC
Pediatric Drug Development - Regulatory challenges and commercial opportunities Although pediatrics represent around two-fifths of the global population the market for pediatric medicines remains relatively ...
The Politics of Pharma (CBRSV042) – Washington, States, and the Courts Impact on the Industry by CBR Pharma Insights, LLC
Politics have a greater direct effect on the pharmaceutical industry than almost any other in the US, and correspondingly, pharma makes considerable investments in election ...
Clinical Development and Trial Design – Developing a Coherent Approach from Beginning to End by CBR Pharma Insights, LLC
A good clinical development plan will ensure success throughout the product lifecycle. In today’s cost constrained environment, the clinical development plan can help ...
See all reports like this >>

More United States Manufacturing, Packaging & Detailing reports

Pharmaceutical Manufacturing by First Research, Inc.
Pharmaceutical ManufacturingBrief Excerpt from Industry Overview Chapter:Companies in this industry manufacture and process pharmaceutical products. Major companies include Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, ...
United States Pharmaceuticals and Healthcare Report Q4 2014 by Business Monitor International
United States Pharmaceuticals and Healthcare Report Q4 2014BMI View: The US pharmaceutical market presents strong commercial opportunities across the industry.Total US pharmaceutical sales reached USD347.2bn ...
Biotechnology Product Manufacturing by First Research, Inc.
Biotechnology Product ManufacturingBrief Excerpt from Industry Overview Chapter:Companies in this industry manufacture drugs, therapies, vaccines, genetically modified food and fuel, and other products based on ...
PharmaPoint: Asthma - US Drug Forecast and Market Analysis to 2023 by GlobalData
PharmaPoint: Asthma - US Drug Forecast and Market Analysis to 2023SummaryAsthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be ...
See all reports like this >>

More United States reports

The 2013-2018 Outlook for Collagen and (hyaluronic Acid) HA-Based Biomaterials in the United States by Icon Group International, Inc.
The 2013-2018 Outlook for Collagen and (hyaluronic Acid) HA-Based Biomaterials in the United StatesThis econometric study covers the latent demand outlook for collagen and (hyaluronic ...
The 2013-2018 Outlook for Relish in the United States by Icon Group International, Inc.
This econometric study covers the latent demand outlook for relish across the states and cities of the United States. Latent demand (in millions of U.S. ...
See all reports like this >>

 

SELECT A LICENSE

    Online Download  USD 3,900  
    Global Site License  USD 9,800  
 
US: 800.298.5699
Int'l: +1.240.747.3093
 

Share this report


    Other tasks

     
     
    Join Alert Me now!
    Receive bi-weekly email alerts on new market research

    Sign up today!